5147-17-1

Basic information

• Product Name: Cyclo(Tyr-Phe)
• Synonyms: Cyclo(Tyr-Phe)
• CAS NO: 5147-17-1
• Molecular Formula: C₁₈H₁₈N₂O₃
• Molecular Weight: 310.34712
• Mol File: 5147-17-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclo(Tyr-Phe)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclo(Tyr-Phe)(5147-17-1)
• EPA Substance Registry System: Cyclo(Tyr-Phe)(5147-17-1)

Safety Data

• Hazardous Substances Data: 5147-17-1(Hazardous Substances Data)

Upstream product

• 861098-78-4 (3S,6S)-3-benzyl-6-(p-(benzyloxy)benzyl)piperazine-2,5-dione 
• 496064-58-5 (S)-2-[(S)-3-(4-Benzyloxy-phenyl)-2-tert-butoxycarbonylamino-propionylamino]-3-phenyl-propionic acid methyl ester 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 63779-73-7 H-Tyr(OBzl)-Phe-OMe 
• 3081-24-1 H-Phe-OEt 
• 1080-06-4 L-Tyr-OMe 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 66076-54-8 N-tert-butyloxycarbonyl-L-phenylalanine-L-tyrosine methyl ester 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 3417-91-2 L-tyrosine methyl ester HCl 
• 60142-81-6 H-Tyr-Phe-OMe*HCl 
• 60-18-4 L-tyrosine 
• 55288-06-7 H-Phe-Tyr-OMe 

Relevant articles and documents

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens

Microorganisms embedded in a biofilm are significantly more resistant to antimicrobial agents and the defences of the human immune system, than their planktonic counterpart. Consequently, compounds that can inhibit biofilm formation are of great interest for novel therapeutics. In this study, a screening approach was used to identify novel cyclic dipeptides that have anti-biofilm activity against oral pathogens. Five new active compounds were identified that prevent biofilm formation by the cariogenic bacterium Streptococcus mutans and the pathogenic fungus Candida albicans. These compounds also inhibit the adherence of microorganisms to a hydroxylapatite surface. Further investigations were conducted on these compounds to establish the structure–activity relationship, and it was deduced that the common cleft pattern is required for these molecules to act effectively against biofilms.

Marine natural occurring 2,5-diketopiperazines: Isolation, synthesis and optical properties

Seven 2,5-diketopiperazines (DKPs) were isolated from the Fijian marine sponge Acanthella cavernosa. NMR and circular dichroism (CD) comparison with synthetic L-L DKPs allowed us to determine unambiguously the L-L absolute configuration of the natural DKPs. This work initiated the setting up of an optical properties database of natural DKPs, including specific rotation and CD.